Showing papers in "Vaccine in 2016"

TL;DR: Overall, HCPs need more support to manage the quickly evolving vaccine environment as well as changing public, especially those who are reluctant or refuse vaccination, as they are faced with time constraints, increased workload and limited resources, and often have inadequate information or training support to address parents' questions.

TL;DR: The knowledge of the persistence of Sars-specific celullar immunity targeting the viral structural proteins in SARS-recovered individuals is important in the design and development of SARS vaccines, which are currently unavailable.

TL;DR: The role of Tregs in the tumor microenvironment and in cancer progression focusing on human studies is critically examined and the impact of current therapeutic modalities on Treg biology and the therapeutic opportunities for targeting T Regs to enhance anti-tumor immune responses and clinical benefits are discussed.

TL;DR: High-quality recommendations were strongly associated with HPV vaccination behavior, but only about one-third of parents received them; interventions are needed to improve not only whether, but how providers recommend HPV vaccination for adolescents.

TL;DR: The results revealed that vaccine hesitancy is present in all four countries among vaccine providers and the most important concern across all countries was the fear of vaccine side effects.

TL;DR: Understanding the mechanisms of the generation, expansion, recruitment and activation of myeloid-derived suppressor cells is required for the development of novel strategies for tumor immunotherapy.

TL;DR: This case definition assign levels of confidence to categorisation of births as preterm, utilising assessment modalities which may be available across different settings to enable systematic safety evaluation of vaccine clinical trials and post-implementation programmes of immunisations in pregnancy.

TL;DR: The dual potential roles that the inflammatory cytokine IL-8 plays in promoting tumor resistance by enhancing the immunosuppressive microenvironment and activating EMT are highlighted, and the potential for targeting the IL- 8/IL-8 receptor axis to combat these various resistance mechanisms is discussed.

TL;DR: This review details recent breakthroughs in the design of nano-particulate vaccine carriers, including liposomes, polymeric nanoparticles, and inorganic nanoparticles.

TL;DR: A practical taxonomy to organise the myriad possible root causes of a gap in vaccination coverage rates is developed, which has already facilitated mutual understanding of the primary determinants of suboptimal coverage within inter-sectorial working groups, a first step towards them developing targeted and effective solutions.

TL;DR: Implementing a UAS could increase vaccine availability and decrease costs in a wide range of settings and circumstances if the drones are used frequently enough to overcome the capital costs of installing and maintaining the system.

TL;DR: The reported data suggest that the prime-boost strategy as a combination of vaccines (i.e., heterologous prime- boost) may be better than a single vaccine for protection against infectious diseases.

TL;DR: This review summarizes current RSV vaccine research and development, including an overview of the vaccine platforms being used, the development stage of individual vaccine candidates, and gaps to be addressed to facilitate use of these vaccines to meet global health needs.

TL;DR: This is the first large scale randomised trial of different times of vaccination and simple manipulation is cost neutral and may improve protection from influenza in older adults.

TL;DR: Leishmaniasis is a vector-borne neglected tropical disease caused by a protozoan parasite of the genus Leishmania and transmitted to humans by the bite of a sand fly, and both VL and CL vaccines have been shown to be cost-effective in economic modeling studies.

TL;DR: A landscape of Shigella vaccine development efforts is provided, including live attenuated, formalin-killed whole-cell, glycoconjugate, subunit, and novel antigen vaccines (e.g., Type III secretion system and outer membrane proteins).

TL;DR: The vaccine was generally well tolerated, although local and systemic adverse events were significantly more common in the vaccine group, and the efficacy did not reach conventional levels of significance.

TL;DR: All studies reviewed found an increase in vaccine coverage when pharmacists were involved in the immunization process, regardless of role (educator, facilitator, administrator) or vaccine administered, when compared to vaccine provision by traditional providers without pharmacist involvement.

TL;DR: Unlike most drugs, whose benefit is restricted to the individual who takes the drug, prophylactic vaccines have the potential for far-reaching effects that encompass health service utilisation, general health and wellbeing, cognitive development and, ultimately, economic productivity.

TL;DR: The World Health Organization convened the first RSV vaccine consultation in 15 years on the 23rd and 24th of March, 2015 in Geneva, Switzerland to provide guidance on clinical endpoints and development pathways for vaccine trials with a focus on considerations of low- and middle-income countries.

TL;DR: Vaccinated seronegative individuals of all ages were at increased risk of developing hospitalized disease during a subsequent wild type DENV infection, and the implications of the observed mixture of DENV protection and enhanced disease in CYD vaccinees are discussed.

TL;DR: The first prospective controlled cohort study in women and infants on the effects of using Boostrix(®), a combined tetanus, diphtheria and acellular pertussis vaccine, during pregnancy to assess possible interference with infant immune responses is reported.

TL;DR: One of the strategic objectives of the 2011-2020 Global Vaccine Action Plan is for the benefits of immunisation to be equitably extended to all people, but this approach encompasses special groups at increased risk of vaccine-preventable diseases, such as preterm infants and pregnant women, as well as those with chronic and immune-compromising medical conditions or at increasedrisk of disease due to immunosenescence.

TL;DR: Given the rapid onset and progression within hours of birth as well as the deficiencies in IAP strategies and absence of a solution for preventing LOD, it is clear that administration of a suitable vaccine in pregnancy could provide a better solution in all settings.

TL;DR: The 59% of countries reporting that they had policies are wealthier, use more new or under-utilized vaccines, and have stronger immunization systems, according to the 2014 revision of the JRF, which permitted a global assessment of national influenza immunization policies.

TL;DR: The data confirms that these MGF360 and MGF530/505 genes have roles in suppressing induction of type I IFN and is a promising route for construction of rationally attenuated ASFV candidate vaccine strains.

TL;DR: Overall, strengthening the contacts and relationships between the health care services and mothers with several children and families with low educational level/low socioeconomic status appear to be an important action to improve vaccination coverage.

TL;DR: Leading cellular vaccine candidates are ETVAX and ACE527, both of which have been found to be safe and immunogenic in Phase 1/2 trials, and impact and economic models suggest favorable vaccine cost-effectiveness, which may help expand market interest in ETEC vaccines.

TL;DR: An overview of efforts to develop HSV-2 vaccines is provided, including a discussion of the clinical need for an HSV vaccine, and status of research and development with an emphasis on recent insights from trials of vaccine candidates in clinical testing.

TL;DR: High quality community-based vaccination coverage surveys are resource-intensive and other monitoring methods provide useful data for programme managers, which should lead to action to improve performance.